No abstract

Background: Statins can improve prognosis of patients with liver cirrhosis by suppressing inflammation and lowering portal pressure.Here, we performed a meta-analysis to evaluate the clinical efficacy of simvastatin in liver cirrhosis patients.Methods: We searched PubMed, EMBASE, and Cochrane library databases for randomized controlled trials targeting simvastatin in patients with liver cirrhosis. The primary and secondary outcomes were the efficacy of simvastatin on clinical outcomes and its safety, respectively.Results: A total of 554 relevant articles were downloaded, of which 9 (comprising 648 participants) were eligible and were finally included in the analysis. Four studies revealed the impact of simvastatin on patient mortality, with the overall death rate found to be significantly lower in the simvastatin relative to the control group [risk ratio (RR): 0.46; 95% confidence interval (CI), 0.29 to 0.73; P < 0.01]. Further analysis of the cause of death showed that simvastatin significantly reduces incidence of fatal bleeding (RR: 0.35; 95% CI, 0.13 to 0.95; P = 0.04), as well as cholesterol [mean difference (MD): −31.48; 95% CI, −52.80 to −10.15; P < 0.01] and triglyceride (MD: −25.88; 95% CI, −49.90 to −1.86; P = 0.03) levels. At the same time, simvastatin did not significantly elevate levels of alanine aminotransferase (ALT) (MD: 2.34; 95% CI, −31.00 to 35.69; P = 0.89) and was not associated with incidence of other side effects.Conclusions: The use of simvastatin in cirrhotic patients lowers mortality rates by suppressing incidences of fatal bleeding.